AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLAstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing Share XAZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLhttps://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/
AbbVie makes case for Humira follow-on upadacitinib at EULARThe summer medical conference season is well and truly upon us and much of the focus this week Share XAbbVie makes case for Humira follow-on upadacitinib at EULARhttps://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
AbbVie pulls phase 3 ADC trials in glioblastoma after survival missAbbVie is the latest company to have an investigational drug for glioblastoma multiforme (GBM) – an aggressive form Share XAbbVie pulls phase 3 ADC trials in glioblastoma after survival misshttps://pharmaphorum.com/news/abbvie-pulls-phase-3-adc-trials-in-glioblastoma-after-survival-miss/
Roche and AbbVie’s Venclexta approved in CLLRoche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for Share XRoche and AbbVie’s Venclexta approved in CLLhttps://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/
Boehringer settles Humira lawsuit, joins biosimilar queue in USBoehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has Share XBoehringer settles Humira lawsuit, joins biosimilar queue in UShttps://pharmaphorum.com/news/boehringer-settles-humira-lawsuit-joins-biosimilar-queue-in-us/
NHS trumpets Hep C deal, quietly drops 2025 elimination target after legal rowNHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate Share XNHS trumpets Hep C deal, quietly drops 2025 elimination target after legal rowhttps://pharmaphorum.com/news/nhs-trumpets-hep-c-deal-quietly-drops-2025-elimination-target-after-legal-row/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
AbbVie’s psoriasis drug Skyrizi approved in JapanAbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this Share XAbbVie’s psoriasis drug Skyrizi approved in Japanhttps://pharmaphorum.com/news/abbvies-psoriasis-drug-skyrizi-approved-in-japan/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
